Drug data last refreshed 29m ago · AI intelligence enriched 2w ago
HELIUM, USP is an inhalational gas product in pre-launch development by Advanced Solutions Life Sciences. The specific therapeutic indications and mechanism of action have not been disclosed in available regulatory documentation. This product represents an emerging non-traditional modality in pharmaceutical development.
Early-stage development phase offers limited visibility into commercial trajectory; team structure and headcount remain undefined pending regulatory clearance.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Advanced Solutions Life Sciences is hiring 1 role related to this product
No linked career opportunities currently identified for this product. Working on HELIUM, USP during pre-launch carries high execution risk but potential upside in establishing early-stage expertise in an emerging inhalational gas therapeutic space.